Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients
Metrics: PDF 2289 views | HTML 2602 views | ?
Xia-Ying Kuang1,2,*, Li Chen1,2,*, Zhi-Jie Zhang4, Yi-Rong Liu1,2, Yi-Zi Zheng1,2, Hong Ling2, Feng Qiao2, Shan Li2, Xin Hu2, Zhi-Ming Shao1,2,3
1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3Institutes of Biomedical Science, Fudan University, Shanghai, China
4Department of Epidemiology and Biostatistics, School of Public Health, Fudan University, Shanghai, China
*These authors have contributed equally to this work
Zhi-Ming Shao, e-mail: [email protected]
Xin Hu, e-mail: [email protected]
Keywords: stathmin, phosphorylation, breast cancer, prognostic model, paclitaxel
Received: March 11, 2015 Accepted: June 01, 2015 Published: June 13, 2015
Currently, Stathmin1 (STMN1) and phospho-STMN1 levels in breast cancers and their clinical implications are unknown. We examined the expression of STMN1 and its serine phospho-site (Ser16, Ser25, Ser38, and Ser63) status by immunohistochemistry. Using Cox regression analysis, a STMN1 expression signature and phosphorylation profile plus clinicopathological characteristics (STMN1-E/P/C) was developed in the training set (n = 204) and applied to the validation set (n = 106). This tool enabled us to separate breast cancer patients into high- and low-risk groups with significantly different disease-free survival (DFS) rates (P < 0.001). Importantly, this STMN1-E/P/C model had a greater prognostic value than the traditional TNM classifier, especially in luminal subtype breast cancer (P = 0.002). Further analysis showed that patients in the low-risk group would benefit more from adjuvant paclitaxel-based chemotherapy (P = 0.002). In conclusion, the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.